BioTime
This article was originally published in The Gray Sheet
Executive Summary
Grosses $4.6 mil. in secondary offering of 900,000 shares at $5.125. The net proceeds from the offering bring BioTime's cash on hand to about $6 mil., which will be used to support product development and testing programs and an effort "to seek FDA approval of one or more versions of [the firm's] blood substitute and organ-preservation solutions," the company says. The Berkeley, California firm's shares recently began trading on the Boston Stock Exchange under the symbol "BTM," and continue to trade on the NASDAQ exchange under "BTIM" ("The Gray Sheet" Jan. 13, 1992, p. 28)